Society AC. Cancer Facts and Fig. 2021. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

Brackstone M, et al. Management of the Axilla in early-stage breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39(27):3056–82.

Article  PubMed  Google Scholar 

Yan M, Abdi MA, Falkson C. Axillary Management in breast Cancer patients: a Comprehensive Review of the key trials. Clin Breast Cancer. 2018;18(6):e1251–9.

Article  PubMed  Google Scholar 

Plichta JK. Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview. Chin Clin Oncol. 2019;8(S1):S11.

Article  PubMed  Google Scholar 

Amin MB, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.

Article  PubMed  Google Scholar 

Estourgie SH, et al. Lymphatic drainage patterns from the breast. Ann Surg. 2004;239(2):232–7.

Article  PubMed  PubMed Central  Google Scholar 

Chen X, et al. Ultrasound as a replacement for physical examination in clinical staging of axillary lymph nodes in breast cancer patients. Thorac Cancer. 2020;11(1):48–54.

Article  PubMed  Google Scholar 

Hodler J, Kubik-Huch RA, von Schulthess GK, editors. Diseases of the chest, breast, heart and vessels 2019–2022: diagnostic and interventional imaging. Editors: Cham (CH); 2019.

Google Scholar 

Marino MA, et al. Lymph Node Imaging in patients with primary breast Cancer: concurrent diagnostic tools. Oncologist. 2020;25(2):e231–42.

Article  PubMed  Google Scholar 

Krag DN, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.

Article  CAS  PubMed  Google Scholar 

Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.

Article  PubMed  PubMed Central  Google Scholar 

Ashikaga T, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.

Article  PubMed  PubMed Central  Google Scholar 

Land SR, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical adjuvant breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28(25):3929–36.

Article  PubMed  PubMed Central  Google Scholar 

Giuliano AE, et al. Effect of Axillary Dissection vs no Axillary dissection on 10-Year overall survival among women with invasive breast Cancer and Sentinel Node Metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–26.

Article  PubMed  PubMed Central  Google Scholar 

Giuliano AE, et al. Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary dissection in patients with Sentinel Lymph Node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264(3):413–20.

Article  PubMed  Google Scholar 

Lucci A, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–63.

Article  PubMed  Google Scholar 

Caudle AS, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011;18(9):2407–12.

Article  PubMed  PubMed Central  Google Scholar 

Gainer SM, et al. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19(10):3152–8.

Article  PubMed  Google Scholar 

Caudle AS, et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012;19(10):3144–51.

Article  PubMed  PubMed Central  Google Scholar 

Liu M, et al. The feasibility of the ACOSOG Z0011 criteria to Chinese breast Cancer patients: a Multicenter Study. Sci Rep. 2015;5:15241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weiss A, et al. Expanding implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018;18(4):276–81.

Article  PubMed  Google Scholar 

Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.

Article  PubMed  PubMed Central  Google Scholar 

Bartels SAL, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981–22023 AMAROS trial. J Clin Oncol. 2022;epubaheadofprint. https://doi.org/10.1200/JCO.22.01565.

Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23– 01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.

Article  PubMed  PubMed Central  Google Scholar 

Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23– 01): 10-year follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2018;19:1385–93.

Article  PubMed  Google Scholar 

Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of Axillary Lymph Nodes Compared with complete dissection in T1-2 breast Cancer patients presenting one or two metastatic Sentinel Lymph nodes: the SINODAR-ONE Multicenter Randomized Clinical Trial. Ann Surg Oncol. 2022;29(9):5732–44. https://doi.org/10.1245/s10434-022-11866-w.

Article  PubMed  Google Scholar 

de Boniface J, Filtenborg Tvedskov J, Rydén L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163–75.

Article  PubMed  Google Scholar 

McGuire KP. Axillary dissection - the Bell tolls for Thee. N Engl J Med. 2024;390(13):1231–2. https://doi.org/10.1056/NEJMe2401805.

Article  PubMed  Google Scholar 

Fisher B, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312(11):674–81.

Article  CAS  PubMed  Google Scholar 

Fisher B, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.

Article  PubMed  Google Scholar 

Gentilini OD, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND Randomized Clincial Trial. JAMA Oncol. 2023;9(11):1557–64.

Article  PubMed  PubMed Central  Google Scholar 

Kalinksy K, et al. 21 gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47.

Article  Google Scholar 

Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549–55.

Article  PubMed  PubMed Central  Google Scholar 

Boughey JC, et al. Tumor biology correlates with rates of breast conserving surgery and pathologic complete response after neoadjuvant chmeotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608–16.

Article  PubMed  Google Scholar 

Samiei S, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease. JAMA Surg. 2021;156(6):e210891.

Article